Value added Medicines | Online SummitExecutive summaryEmpowering the healthcarecommunity by improvingexisting treatments• Innovating on existing molecules in the form of repurposing,reformulation and combination of therapies has the potential to delivertimely and...
Háziorvosok is felírhatják a favipiravirt COVID-19-betegeknekAkadémikusok javaslatára Mit kell tudni a gyógyszerről és milyen esetekben alkalmazható? Erről nyilatkozott az mta.hu-nak Keserű György Miklós akadémikus, a Természettudományi Kutatóközpont Gyógyszerkémiai...
Koronavírus elleni gyógyszertgyártó üzemet adtak át PilisborosjenőnEredményes az Egészségipari Támogatási Program,Magyarország önellátóvá vált az orvosi maszkok gyártásában, a kórházi gumikesztyűk előállításában, most pedig a vírus elleni védekezéshez szükséges...
Today marks the third anniversary of the European Medicines Verification (“EMVS”) System Go-live. This unique system ensures patient safety by detecting falsified medicines in the legal supply chain. The EMVS interconnects 2.500 pharmaceutical companies, 4.000 wholesale distribution authorisation holders, 100.000 pharmacies, 6.000 hospital pharmacies and 500 dispensing doctors in 29 countries.
To celebrate the occasion, Andreas Walter, the General Manager of EMVO, highlights some of the biggest achievements of the system.
“The EMVS is a challenging project. It’s a complex landscape and there are many parties involved. Yet it has become evident that working together towards the same goal is not only feasible but has proven to be successful. EMVO continues to support the EMVS Community by strengthening the key priorities and encouraging mutual collaboration and commitment of all users.
Close collaboration has been demonstrated by the smooth running of the European Change Control Board (CCB, the central governance body within the EMVS), which has overseen the governance and implementation of over 300 changes since its inception, as well as the reduction of the overall rate of false-positive alerts, which decreased from 0,33% to 0,21% in 2021.
Within EMVO, we are dedicated to achieving the shared mission – patient safety. In 2022, EMVO will focus on operational excellence, alert management and supporting full compliance with legislation. These priorities are demonstrated in our core projects – e.g. the implementation of the AMS (Alert Management System) to support MAHs (Marketing Authorisation Holders) and EMVS end-users in maximising the efficiency of alert management.
We also encourage the involvement of the NCAs and the EU COM and trust that their assistance will help the EMVS Community in pursuing the shared mission and address remaining challenges at European and national level. The EMVS is also looking forward to welcoming Greece and Italy and is working diligently to ensure their smooth on-boarding.
I would like to take this opportunity to thank all those involved – our Stakeholders*, the National Medicines Verification Organisations (NMVOs), the MAHs/On-boarding Partners (OBPs), the authorities and end-users (pharmacies, hospitals, wholesalers) – for the ongoing hard work. Patient health and safety can only be protected when we work together!”
Forrás: EMVO